Blueprint
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of September 2016
Commission File Number: 001-11960
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
1 September 2016 14:30
Transparency Directive
Voting Rights and Capital
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. On 31 August 2016 the issued share capital of AstraZeneca PLC with voting rights is 1,264,983,797 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights
in AstraZeneca PLC is 1,264,983,797.
The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in
inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
|
Media Enquiries
|
|
|
|
Neil Burrows
|
UK/Global
|
+44 203 749 5637
|
|
Vanessa Rhodes
|
UK/Global
|
+44 203 749 5736
|
|
Karen Birmingham
|
UK/Global
|
+44 203 749 5634
|
|
Rob Skelding
|
UK/Global
|
+44 203 749 5821
|
|
Jacob Lund
|
Sweden
|
+46 8 553 260 20
|
|
Michele Meixell
|
US
|
+1 302 885 2677
|
|
Investor Relations
|
|
|
|
UK
|
|
|
|
Thomas Kudsk Larsen
|
|
+44 203 749 5712
|
|
Craig Marks
|
Finance, Fixed Income, M&A
|
+44 7881 615 764
|
|
Nick Stone
|
Respiratory & Autoimmunity
|
+44 203 749 5716
|
|
Henry Wheeler
|
Oncology
|
+44 203 749 5797
|
|
Christer Gruvris
|
Infection & Neuroscience
|
+44 203 749 5711
|
|
US
|
|
|
|
Lindsey Trickett
|
Cardiovascular & Metabolic Diseases
|
+1 240 543 7970
|
|
Mitchell Chan
|
Oncology
|
+1 240 477 3771
|
|
Toll-free
|
|
+1 866 381 7277
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
-ENDS-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AstraZeneca PLC
Date: 01 September 2016
By: /s/ Adrian Kemp
Name: Adrian Kemp
Title: Company Secretary